High protection and transmission-blocking immunity elicited by single-cycle SARS-CoV-2 vaccine in hamsters

单周期SARS-CoV-2疫苗在仓鼠体内诱导产生高保护性和阻断传播的免疫力

阅读:4
作者:Martin Joseph Lett # ,Fabian Otte # ,David Hauser # ,Jacob Schön ,Enja Tatjana Kipfer ,Donata Hoffmann ,Nico J Halwe ,Angele Breithaupt ,Lorenz Ulrich ,Tobias Britzke ,Jana Kochmann ,Björn Corleis ,Yuepeng Zhang ,Lorena Urda ,Vladimir Cmiljanovic ,Christopher Lang ,Martin Beer ,Christian Mittelholzer ,Thomas Klimkait

Abstract

Vaccines have played a central role in combating the COVID-19 pandemic, but newly emerging SARS-CoV-2 variants are increasingly evading first-generation vaccine protection. To address this challenge, we designed "single-cycle infection SARS-CoV-2 viruses" (SCVs) that lack essential viral genes, possess distinctive immune-modulatory features, and exhibit an excellent safety profile in the Syrian hamster model. Animals intranasally vaccinated with an Envelope-gene-deleted vaccine candidate were fully protected against an autologous challenge with the SARS-CoV-2 virus through systemic and mucosal humoral immune responses. Additionally, the deletion of immune-downregulating viral genes in the vaccine construct prevented challenge virus transmission to contact animals. Moreover, vaccinated animals displayed neither tissue inflammation nor lung damage. Consequently, SCVs hold promising potential to induce potent protection against COVID-19, surpassing the immunity conferred by natural infection, as demonstrated in human immune cells.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。